Synaptogenix, Inc., a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis ("MS"),...
Jupiter Neurosciences, Inc., announced the completion of its Phase I clinical trial with its proprietary JOTROL™, an enhanced formulation of resveratrol with increased bioavailability....
Jacobio Pharmaceuticals announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combination therapy with Cetuximab at Peking University Cancer Hospital...
AMRA Medical, a ground-breaking digital health company and global leader in body composition analysis offering medical device and medical research services, announced that AMRA...
Fluence Analytics, a venture-backed global leader in continuous polymer reaction monitoring and control, announced a further expansion of its biopharmaceutical product line with the...
